A214450 Stock Overview
Operates as a biopharmaceutical company primarily in South Korea. More details
| Snowflake Score | |
|---|---|
| Valuation | 6/6 |
| Future Growth | 5/6 |
| Past Performance | 5/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for A214450 from our risk checks.
PharmaResearch Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩200,500.00 |
| 52 Week High | ₩241,500.00 |
| 52 Week Low | ₩86,800.00 |
| Beta | 0.49 |
| 11 Month Change | -13.02% |
| 3 Month Change | 12.01% |
| 1 Year Change | 77.43% |
| 33 Year Change | 153.48% |
| 5 Year Change | 482.85% |
| Change since IPO | 75.11% |
Recent News & Updates
PharmaResearch Co., Ltd. (KOSDAQ:214450) Stock Rockets 26% As Investors Are Less Pessimistic Than Expected
Aug 15
Here's Why We Think PharmaResearch (KOSDAQ:214450) Might Deserve Your Attention Today
May 21Recent updates
PharmaResearch Co., Ltd. (KOSDAQ:214450) Stock Rockets 26% As Investors Are Less Pessimistic Than Expected
Aug 15Here's Why We Think PharmaResearch (KOSDAQ:214450) Might Deserve Your Attention Today
May 21PharmaResearch Co., Ltd.'s (KOSDAQ:214450) 33% Share Price Surge Not Quite Adding Up
Apr 09Is Pharma Research Products (KOSDAQ:214450) A Risky Investment?
Mar 23Are Investors Undervaluing Pharma Research Products Co., Ltd (KOSDAQ:214450) By 50%?
Mar 05Should You Be Adding Pharma Research Products (KOSDAQ:214450) To Your Watchlist Today?
Feb 17Introducing Pharma Research Products (KOSDAQ:214450), A Stock That Climbed 65% In The Last Year
Feb 02
Pharma Research Products Co., Ltd (KOSDAQ:214450) Is Yielding 0.5% - But Is It A Buy?
Jan 20Here's What Pharma Research Products Co., Ltd's (KOSDAQ:214450) Shareholder Ownership Structure Looks Like
Jan 07Declining Stock and Solid Fundamentals: Is The Market Wrong About Pharma Research Products Co., Ltd (KOSDAQ:214450)?
Dec 23Is Pharma Research Products (KOSDAQ:214450) Using Too Much Debt?
Dec 08Is Pharma Research Products Co., Ltd (KOSDAQ:214450) Trading At A 43% Discount?
Nov 25Shareholder Returns
| A214450 | KR Biotechs | KR Market | |
|---|---|---|---|
| 7D | -4.5% | -3.0% | 2.3% |
| 1Y | 77.4% | 22.4% | -3.8% |
Return vs Industry: A214450 exceeded the KR Biotechs industry which returned 22.4% over the past year.
Return vs Market: A214450 exceeded the KR Market which returned -3.8% over the past year.
Price Volatility
| A214450 volatility | |
|---|---|
| A214450 Average Weekly Movement | 6.9% |
| Biotechs Industry Average Movement | 8.1% |
| Market Average Movement | 5.7% |
| 10% most volatile stocks in KR Market | 11.4% |
| 10% least volatile stocks in KR Market | 2.7% |
Stable Share Price: A214450 has not had significant price volatility in the past 3 months compared to the KR market.
Volatility Over Time: A214450's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1993 | 403 | Sang-Soo Jung | www.pharmaresearch.co.kr/kor/ |
PharmaResearch Co., Ltd., together with its subsidiaries, operates as a biopharmaceutical company primarily in South Korea. The company offers Re-An eye drops for protecting eyes from corneal damages with various causes; JBP PLAMON injection, a brown ampoule containing a pale yellow transparent liquid; ZADAXIN injection, an adjunctive therapy for influenza vaccination in immunocompromised elderly patients; PLACENTEX injection for the treatment and tissue restoration of wounds; CLEVIEL VOLUME to temporarily improve facial wrinkles in adults through the physical restoration; Rejuran HB plus which is used for temporary improvement of adult's crow's feet wrinkles; Rejuvenex injection, a tissue regeneration activator that regenerates connective tissues, including ligament, tendon, skin, etc.; and Rejuvenex cream, which treats the wound through rapid tissue regeneration. It also provides REJURAN, a medical device for face (especially eye, perioral area), neck, Décolleté, hands, etc; CLEVIEL prime plus and contour plus with lidocaine medical devices; D+CELL 350 TRA I; and REJURAN moisturizer for daily skin protection, as well as REJUVENEX SCULPT V; REJURAN concentrate for sensitive and aged skin; REJURAN healing eye gel and mask; REJURAN sunscreen that protects skin from UV rays; and REJURAN recover soothing mask.
PharmaResearch Co., Ltd. Fundamentals Summary
| A214450 fundamental statistics | |
|---|---|
| Market cap | ₩2.09t |
| Earnings (TTM) | ₩90.74b |
| Revenue (TTM) | ₩296.59b |
23.0x
P/E Ratio7.0x
P/S RatioIs A214450 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A214450 income statement (TTM) | |
|---|---|
| Revenue | ₩296.59b |
| Cost of Revenue | ₩85.59b |
| Gross Profit | ₩211.00b |
| Other Expenses | ₩120.26b |
| Earnings | ₩90.74b |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 8.73k |
| Gross Margin | 71.14% |
| Net Profit Margin | 30.60% |
| Debt/Equity Ratio | 6.3% |
How did A214450 perform over the long term?
See historical performance and comparison